PURPOSE: Excess histone deacetylase (HDAC) activity can induce hypoacetylation of histone and nonhistone protein substrates, altering gene expression patterns and cell behavior potentially associated with malignant transformation. However, HDAC expression and protein acetylation have not been studied in the context of breast cancer progression. EXPERIMENTAL DESIGN: We assessed expression levels of acetylated histone H4 (ac-H4), ac-H4K12, ac-tubulin, HDAC1, HDAC2, and HDAC6 in 22 reduction mammoplasties and in 58 specimens with synchronous normal epithelium, ductal carcinoma in situ (DCIS), and invasive ductal carcinoma (IDC) components. Differences among groups were tested for significance using nonparametric tests. RESULTS: From normal epithelium to DCIS, there was a marked reduction in histone acetylation (P < 0.0001). Most cases showed similar levels of acetylation in DCIS and IDC, although some showed further reduction of ac-H4 and ac-H4K12 from DCIS to IDC. Expression of HDAC1, HDAC2, and HDAC6 was also significantly reduced but by a smaller magnitude. Greater reductions of H4 acetylation and HDAC1 levels were observed from normal to DCIS in estrogen receptor-negative compared with estrogen receptor-positive, and in high-grade compared with non-high-grade tumors. CONCLUSION: Overall, there was a global pattern of hypoacetylation associated with progression from normal to DCIS to IDC. These findings suggest that the reversal of this hypoacetylation in DCIS and IDC could be an early measure of HDAC inhibitor activity.
PURPOSE: Excess histone deacetylase (HDAC) activity can induce hypoacetylation of histone and nonhistone protein substrates, altering gene expression patterns and cell behavior potentially associated with malignant transformation. However, HDAC expression and protein acetylation have not been studied in the context of breast cancerprogression. EXPERIMENTAL DESIGN: We assessed expression levels of acetylated histone H4 (ac-H4), ac-H4K12, ac-tubulin, HDAC1, HDAC2, and HDAC6 in 22 reduction mammoplasties and in 58 specimens with synchronous normal epithelium, ductal carcinoma in situ (DCIS), and invasive ductal carcinoma (IDC) components. Differences among groups were tested for significance using nonparametric tests. RESULTS: From normal epithelium to DCIS, there was a marked reduction in histone acetylation (P < 0.0001). Most cases showed similar levels of acetylation in DCIS and IDC, although some showed further reduction of ac-H4 and ac-H4K12 from DCIS to IDC. Expression of HDAC1, HDAC2, and HDAC6 was also significantly reduced but by a smaller magnitude. Greater reductions of H4 acetylation and HDAC1 levels were observed from normal to DCIS in estrogen receptor-negative compared with estrogen receptor-positive, and in high-grade compared with non-high-grade tumors. CONCLUSION: Overall, there was a global pattern of hypoacetylation associated with progression from normal to DCIS to IDC. These findings suggest that the reversal of this hypoacetylation in DCIS and IDC could be an early measure of HDAC inhibitor activity.
Authors: Liwen Zhang; Xiaodan Su; Shujun Liu; Amy R Knapp; Mark R Parthun; Guido Marcucci; Michael A Freitas Journal: J Proteome Res Date: 2007-01 Impact factor: 4.466
Authors: Mahmoud A Mohamed; Philipp A Greif; James Diamond; Osama Sharaf; Perry Maxwell; Rodolfo Montironi; Robert A M Young; Peter W Hamilton Journal: BJU Int Date: 2007-04 Impact factor: 5.588
Authors: Daryl C Drummond; Charles O Noble; Dmitri B Kirpotin; Zexiong Guo; Gary K Scott; Christopher C Benz Journal: Annu Rev Pharmacol Toxicol Date: 2005 Impact factor: 13.820
Authors: Pamela Münster; Douglas Marchion; Elona Bicaku; Morgen Schmitt; Ji Hyun Lee; Ronald DeConti; George Simon; Mayer Fishman; Susan Minton; Chris Garrett; Alberto Chiappori; Richard Lush; Daniel Sullivan; Adil Daud Journal: J Clin Oncol Date: 2007-05-20 Impact factor: 44.544
Authors: Fabrice Barlési; Giuseppe Giaccone; Marielle I Gallegos-Ruiz; Anderson Loundou; Simone W Span; Pierre Lefesvre; Frank A E Kruyt; Jose Antonio Rodriguez Journal: J Clin Oncol Date: 2007-10-01 Impact factor: 44.544
Authors: Aditya Sudheer Vaidya; Bhargava Karumudi; Emma Mendonca; Antonett Madriaga; Hazem Abdelkarim; Richard B van Breemen; Pavel A Petukhov Journal: Bioorg Med Chem Lett Date: 2012-06-18 Impact factor: 2.823
Authors: Lauren L Atwell; Zhenzhen Zhang; Motomi Mori; Paige Farris; John T Vetto; Arpana M Naik; Karen Y Oh; Philippe Thuillier; Emily Ho; Jackilen Shannon Journal: Cancer Prev Res (Phila) Date: 2015-10-28
Authors: Peter M Wilson; Melissa J Labonte; Shelby C Martin; Stephanie T Kuwahara; Anthony El-Khoueiry; Heinz-Josef Lenz; Robert D Ladner Journal: Invest New Drugs Date: 2013-01-09 Impact factor: 3.850
Authors: Tyler R McCaw; Mei Li; Dmytro Starenki; Mingyong Liu; Sara J Cooper; Rebecca C Arend; Andres Forero; Donald J Buchsbaum; Troy D Randall Journal: Cancer Immunol Immunother Date: 2019-11-12 Impact factor: 6.968
Authors: Yong Zhu; Richard G Stevens; Aaron E Hoffman; Anne Tjonneland; Ulla B Vogel; Tongzhang Zheng; Johnni Hansen Journal: Chronobiol Int Date: 2011-12 Impact factor: 2.877
Authors: Matthew A McBrian; Iman Saramipoor Behbahan; Roberto Ferrari; Trent Su; Ta-Wei Huang; Kunwu Li; Candice S Hong; Heather R Christofk; Maria Vogelauer; David B Seligson; Siavash K Kurdistani Journal: Mol Cell Date: 2012-11-29 Impact factor: 17.970
Authors: Melissa J LaBonte; Peter M Wilson; William Fazzone; Susan Groshen; Heinz-Josef Lenz; Robert D Ladner Journal: BMC Med Genomics Date: 2009-11-30 Impact factor: 3.063